In a report released today, Kostas Biliouris from BMO Capital downgraded Jasper Therapeutics to a Hold, with a price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Hold rating due to a combination of factors surrounding Jasper Therapeutics. The recent updates on Briquilimab’s clinical trial results, particularly in the context of chronic spontaneous urticaria (CSU), have introduced significant uncertainties. The data, while somewhat promising, is clouded by potential manufacturing issues and questions about the drug’s efficacy and safety profile, especially concerning specific product lots.
Furthermore, the competitive landscape and market conditions add to the complexity. Jasper Therapeutics faces challenges such as financing concerns and development delays compared to competitors. These factors contribute to a cautious outlook, leading to a Hold rating as investors may remain hesitant until clearer results and resolutions to these uncertainties are presented.